Facebook
  1. Home
  2. News & Events
  3. In the News

In the News

ICON experts frequently author or contribute to industry trade press.

Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.

  • irish-times

    To advance in life sciences we must be more ambitious and prioritise public investment in research

    In this article from the Irish Times Life Sciences and Stem supplement, Barry Balfe, President, ICON Pharma Solutions, outlines his views on how Ireland’s life sciences sector can continue to grow and attract investment.

  • EPR-Logo-Thumbnail-(1)

    The move to greener clinical development

    Sustainability requires a layered approach that balances operational feasibility and with greener practices. Sean Morgan, Director of Clinical Supplies Management, discusses how ICON is tackling issues like kit waste, carbon emissions and ethical supply chains.

  • pharmatimes

    To be precise: How oncology therapies can stand out in a diverse, uncertain landscape

    Targeted product profiles and biomarkers for patient screening are essential elements of success for oncology treatment developers, according to our recent survey. This article explores why both prove challenging for drug developers.

  • clinical-trials-arena

    Half of pharma and biotech companies using AI and big data

    This news piece from Clinical Trials Arena provides an overview of the findings of ICON’s recent Digital Disruption survey, which found sentiment towards artificial intelligence and digital tools in the clinical research sector is positive.

  • pharmaphorum

    Outcome measures: Patients beyond endpoints

    The evolving regulatory requirement to put patients at the centre of the drug development process – patient-centric from end to end – means pharmaceutical sponsors must design clinical trials with patient-centred outcomes in mind.

  • EPR-Logo-Thumbnail-(1)

    Curated and customised outsourcing

    As the outsourcing market evolves, pharmaceutical businesses are reassessing their strategies to better insulate themselves against the pressure of compounding macroeconomic constraints, including a looming patent cliff, rising costs and developmental risks.

  • award logo

    Women Mean Business (WMB) Businesswoman Award 2024

    Following her receipt of the WMB Businesswoman Award 2024, Rose Kidd, President, Operations Delivery is interviewed by Women Mean Business on her role, the opportunities for the life sciences industry and her views on how we can support more women to progress STEM careers.

  • Journal for Clinical Studies_JCS_ logo

    Striking the right balance between transparency and privacy in clinical trial data sharing

    In this article, our experts explore how to strike the right balance between adequately anonymising clinical trial data to protect participant privacy and company assets, while still preserving its value for research purposes (see page 16).

  • pharmavoice

    How AI can manage the risks and costs of postmarketing requirements

    Postmarketing requirements (PMRs) for drug development are commonly required to gather data on a product’s longer-term safety, efficacy and optimal use. Carefully applied AI and machine learning offers the potential for better management of PMRs.

  • pharmaphorum

    Strategies for commercialising oncology treatments for young adults

    This article explores the imperatives and strategies for commercialising oncology treatments targeting young adults, highlighting the need for innovative regulatory and commercial strategies to ensure successful market entry and improved patient outcomes.